Loading…
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-101M | $-103M | $-95M | -49.8% | - | - |
| 2024 | $0M | $-78M | $-79M | $-73M | -27.3% | - | - |
| 2023 | $0M | $-39M | $-47M | $-38M | -61.9% | -100.0% | - |
| 2022 | $11M | $-7M | $-7M | $-8M | -11.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 10.79 | 0 | 0 | 0 |
| Cost Of Revenue | 6.18 | 0 | 0 | 0 |
| Gross Profit | 4.62 | 0 | 0 | 0 |
| Operating Expense | 12.01 | 40.94 | 66.80 | 113.56 |
| Operating Income | -7.39 | -40.94 | -66.80 | -113.56 |
| EBITDA | -7.14 | -39.04 | -78.07 | -100.80 |
| EBIT | -7.39 | -40.02 | -80.38 | -104.05 |
| Pretax Income | -7.27 | -40.11 | -80.43 | -104.43 |
| Tax Provision | 0 | -2.65 | -2.10 | -0.79 |
| Net Income | -7.27 | -46.51 | -79.28 | -103.12 |
| Net Income Common Stockholders | -7.27 | -46.51 | -79.28 | -103.12 |
| Total Expenses | 18.19 | 40.94 | 66.80 | 113.56 |
| Interest Expense | 0 | 0.08 | 0.05 | 0.38 |
| Interest Income | 0.12 | 0.93 | 10.52 | 8.11 |
| Research And Development | 2.58 | 21.31 | 41.64 | 84.22 |
| Selling General And Administration | 9.43 | 21.06 | 26.61 | 30.23 |
| Normalized EBITDA | -7.14 | -39.04 | -53.98 | -100.80 |
| Normalized Income | -7.27 | -37.45 | -54.87 | -103.64 |
| Basic EPS | -0.50 | -1.74 | -1.23 | -1.40 |
| Diluted EPS | -0.50 | -1.74 | -1.23 | -1.40 |
| Tax Effect Of Unusual Items | 0 | 0 | -0.63 | 0 |
| Tax Rate For Calcs | 0 | 0.07 | 0.03 | 0.01 |
| Total Unusual Items | 0 | 0 | -24.09 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -24.09 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -7.27 | -37.45 | -78.33 | -103.64 |
| Reconciled Depreciation | 0.25 | 0.99 | 2.31 | 3.25 |
| Reconciled Cost Of Revenue | 6.18 | 0 | 0 | 0 |
| Net Interest Income | 0.12 | 0.85 | 10.47 | 7.74 |
| Net Income From Continuing And Discontinued Operation | -7.27 | -46.51 | -79.28 | -103.12 |
| Total Operating Income As Reported | -7.39 | -40.94 | -90.89 | -113.56 |
| Diluted Average Shares | 14.20 | 26.76 | 64.42 | 73.81 |
| Basic Average Shares | 14.20 | 26.76 | 64.42 | 73.81 |
| Diluted NI Availto Com Stockholders | -7.27 | -46.51 | -79.28 | -103.12 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -7.27 | -46.51 | -79.28 | -103.12 |
| Net Income Discontinuous Operations | 0 | -9.05 | -0.95 | 0.51 |
| Net Income Continuous Operations | -7.27 | -37.45 | -78.33 | -103.64 |
| Other Income Expense | 0 | -0.02 | -24.10 | 1.40 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 1.40 |
| Special Income Charges | 0 | 0 | -24.09 | 0 |
| Gain On Sale Of Ppe | 0 | 0 | -0.03 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 24.06 | 0 |
| Earnings From Equity Interest | 0 | -0.02 | -0.01 | 0 |
| Net Non Operating Interest Income Expense | 0.12 | 0.85 | 10.47 | 7.74 |
| Interest Expense Non Operating | 0 | 0.08 | 0.05 | 0.38 |
| Interest Income Non Operating | 0.12 | 0.93 | 10.52 | 8.11 |
| Other Operating Expenses | 0 | -1.43 | -1.45 | -0.88 |
| Selling And Marketing Expense | 2.76 | 0 | 0 | 0 |
| General And Administrative Expense | 6.67 | 21.06 | 26.61 | 30.23 |
| Other Gand A | 5.91 | 21.06 | 26.61 | 30.23 |
| Salaries And Wages | 0.76 | 0 | 0 | 0 |
| Operating Revenue | 10.79 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Perspective Therapeutics, Inc.this co. | CATX | $448M | - | 1.41 | -49.8% | -2.78 |
| 4D Molecular Therapeutics, Inc. | FDMT | $461M | - | 1.00 | -27.7% | -0.45 |
| MiMedx Group, Inc. | MDXG | $458M | 9.64 | 1.78 | 18.9% | 4.00 |
| Pacific Biosciences of California, Inc. | PACB | $456M | - | 81.67 | -10214.5% | -5.12 |
| Candel Therapeutics, Inc. | CADL |
| $453M |
| - |
| 6.53 |
| -73.5% |
| -8.07 |
| Larimar Therapeutics, Inc. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| Myriad Genetics, Inc. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| Peer Median | - | 9.64 | 2.17 | -50.6% | -2.93 | |